Telehealth provider Ro will begin offering single-dose vials of Eli Lilly’s newly approved obesity drug, Zepbound, aiming to streamline access for patients. Starting next year, individuals will be able to receive the injectable treatment through Ro’s online platform, which connects consumers directly to doctors, pharmacists, and prescription services without traditional in-person visits. Zepbound, a once-weekly injectable designed to help with significant weight loss, joins a rapidly expanding class of obesity medications that includes established names like Wegovy.
Keep Reading
Add A Comment